NCT02659384View on ClinicalTrials.gov

Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

December 23, 2016

Primary Completion Date

June 30, 2021

Study Completion Date

March 31, 2022

Conditions
Ovarian Neoplasms
Interventions
DRUG

Bevacizumab

DRUG

atezolizumab

DRUG

acetylsalicylic acid

DRUG

placebo

Trial Locations (12)

Unknown

Assistance Publique - Hopitaux de Paris - Hopital Europeen Georges Pompidou, Paris

Centre Hospitalier Privé Saint-Grégoire, Saint-Grégoire

Academisch Medisch Centrum - Universiteit van Amsterdam, Amsterdam

Leiden University Medical Centre, Leiden

Radboudumc - Radboud University Medical Center Nijmegen, Nijmegen

Institut Catala d'Oncologia - ICO Badalona - Hospital Germans Trias i Pujol (Institut Catala D'Oncologia), Badalona

Hospital Universitario San Carlos, Madrid

Centre Hospitalier Universitaire Vaudois - Lausanne, Lausanne

Centre Hospitalier Universitaire Vaudois, Lausanne

Guy's and St Thomas' NHS - Guy s and St Thomas' NHS - Guy's Hospital, London

Royal Marsden Hospital - Chelsea, London, London

Royal Marsden Hospital - Sutton, Surrey, Sutton

All Listed Sponsors
lead

European Organisation for Research and Treatment of Cancer - EORTC

NETWORK

NCT02659384 - Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer | Biotech Hunter | Biotech Hunter